trial
as of 2026-07-01Antipsychotic and Motor Effects of ACP-103 When Administered in Combination With Haloperidol and Risperidone
NCTId NCT00361166
at a glance
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 2
Status
Completed
Enrollment
400
Study type
Interventional
Allocation
Randomized
Model
Single Group
Masking
Double
Start
2005-08
Primary completion
—
Eligibility
ALL · 18 Years · 65 Years
Interventions & indications
Sponsors
ACADIA Pharmaceuticals Inc.Lead Sponsor
Investigators
1
Daniel van Kammen, MD, PhDStudy Chair
Sites
0 total
Facts & assertions
3 sourced
Enrollment
400
Phase
PHASE2
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
company
indication
investigator